Cargando…

Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?

Detalles Bibliográficos
Autores principales:	Li, Dunhui, Mastaglia, Frank L., Yau, Wai Yan, Chen, Shengdi, Wilton, Steve D., Akkari, Patrick A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804368/ https://www.ncbi.nlm.nih.gov/pubmed/36036206 http://dx.doi.org/10.1002/mds.29201

Ejemplares similares

Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era
por: Li, Dunhui, et al.
Publicado: (2020)

Antisense Oligonucleotide Induction of Progerin in Human Myogenic Cells
por: Luo, Yue-Bei, et al.
Publicado: (2014)

Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
por: Le, Bao T., et al.
Publicado: (2018)

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies
por: McIntosh, Craig S., et al.
Publicado: (2021)

Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?
por: Roberts, Bradley, et al.
Publicado: (2022)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2
por: Gagliardi, Maria, et al.
Publicado: (2022)

miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
por: Suvarna, Vasanti, et al.
Publicado: (2022)

Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides
por: Aung-Htut, May T., et al.
Publicado: (2019)

Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides
por: Scharner, Juergen, et al.
Publicado: (2020)

Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries
por: Adams, Abbie M, et al.
Publicado: (2007)

Antisense Oligonucleotide-Mediated Terminal Intron Retention of the SMN2 Transcript
por: Flynn, Loren L., et al.
Publicado: (2018)

Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
por: Wang, Dali, et al.
Publicado: (2022)

The potential of antisense oligonucleotide therapies for inherited childhood lung diseases
por: Martinovich, Kelly M., et al.
Publicado: (2018)

Proof-of-Concept: Antisense Oligonucleotide Mediated Skipping of Fibrillin-1 Exon 52
por: Cale, Jessica M., et al.
Publicado: (2021)

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016)

Splice-switching antisense oligonucleotides as therapeutic drugs
por: Havens, Mallory A., et al.
Publicado: (2016)

Nonviral delivery systems for antisense oligonucleotide therapeutics
por: Huang, Si, et al.
Publicado: (2022)

Advances in Antisense Oligonucleotide Development for Target Identification, Validation, and as Novel Therapeutics
por: Mansoor, Moizza, et al.
Publicado: (2008)

Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
por: Qiao, Yuanyuan, et al.
Publicado: (2023)

Consequences of Making the Inactive Active Through Changes in Antisense Oligonucleotide Chemistries
por: Zaw, Khine, et al.
Publicado: (2019)

Reduction of integrin alpha 4 activity through splice modulating antisense oligonucleotides
por: Aung-Htut, May T., et al.
Publicado: (2019)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Induction of cryptic pre-mRNA splice-switching by antisense oligonucleotides
por: Ham, Kristin A., et al.
Publicado: (2021)

Improved targeting of miRNA with antisense oligonucleotides
por: Davis, Scott, et al.
Publicado: (2006)

Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic
por: Moreno, Pedro M. D., et al.
Publicado: (2014)

Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities
por: Lange, Jenny, et al.
Publicado: (2022)

Correction to: Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies
por: Li, Dunhui, et al.
Publicado: (2021)

Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies
por: Li, Dunhui, et al.
Publicado: (2021)

Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching
por: Fragall, Clayton T, et al.
Publicado: (2011)

Induction of revertant fibres in the mdx mouse using antisense oligonucleotides
por: Fall, Abbie M, et al.
Publicado: (2006)

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
por: Cole, Tracy A., et al.
Publicado: (2021)

Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
por: Lima, Walt F., et al.
Publicado: (2014)

Targeted delivery of antisense oligonucleotides to pancreatic β-cells
por: Ämmälä, C., et al.
Publicado: (2018)

Effects of combinations of gapmer antisense oligonucleotides on the target reduction
por: Yanagidaira, Mitsugu, et al.
Publicado: (2023)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
por: Bajan, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qfp7kbpahetjtom4mq1dlaas2g